NAD+
Medium EvidenceA coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.
What It Is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for cellular energy metabolism, DNA repair, sirtuin activation, and over 500 enzymatic reactions. While not a peptide, NAD+ is widely discussed alongside peptide protocols due to its role in metabolic optimization and its intersection with peptide targets like MOTS-c and 5-Amino-1MQ (which boosts NAD+ via NNMT inhibition). Intracellular NAD+ levels decline significantly with age — approximately 50% by middle age — and this decline is implicated in mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and age-related metabolic disease. NAD+ precursors (NMN, NR) and direct IV NAD+ infusion are the primary supplementation strategies. A 2024 meta-analysis of 15 randomized controlled trials found that NMN supplementation (250–1200 mg/day) consistently increased blood NAD+ metabolites, with some trials showing improvements in physical performance, insulin sensitivity, and vascular function in older adults. IV NAD+ infusions bypass first-pass metabolism and produce rapid increases in whole-blood NAD+ levels, though clinical evidence for IV routes remains limited to small, non-randomized studies. The CD38 enzyme, which degrades NAD+ and increases with aging and chronic inflammation, has emerged as a key pharmacological target. NAD+ supplementation is not FDA-approved for any medical condition but is commercially available as a dietary supplement (precursors) and through wellness clinics (IV infusions). Long-term safety data beyond 12 months remains limited.
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (RCT, 2026) | 65 healthy adults — NMN and NR at 1,000 mg/day for 14 days | Doubled circulating NAD+ levels; NMN and NR performed comparably | Source |
| Human (2026) | 11 healthy men — 1,200 mg/day NMN for 7 days after intense exercise | Reduced inflammatory signals post-exercise | Source |
| Human (RCT) | Rare diseases with premature aging and DNA damage | Promising therapeutic benefits from NAD+ supplementation | Source |
| Human (RCT) | Chronic NMN supplementation in healthy older men | Elevated blood NAD+ levels; altered muscle function | Source |
Commonly Discussed Benefits
Safety & Cautions
- IV administration should be performed by medical professionals
- Oral precursors (NMN, NR) are available as supplements but NMN's supplement status is legally contested
- FDA ruled in 2022 that NMN cannot be marketed as a dietary supplement
- Optimal dosing and delivery method still being studied
- A 2025 lifespan study showed no difference vs placebo — anti-aging claims remain under investigation
- Clinical results across studies are mixed; not all trials show meaningful benefits
Comparisons
See how NAD+ compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Rajman L. et al. — Therapeutic potential of NAD-boosting molecules. Cell Metab. 2018 PubMed
- [2] Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage — PMC 2026 PubMed
- [3] Updated Review on NMN and NR Mechanisms, Pre-Clinical and Clinical Comparisons — Food Frontiers. 2025 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.
SS-31
High EvidenceA mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.